ArticleFrontiers in endocrinology2026
Association of ultrasound-derived fat fraction with carotid intima-media thickness and carotid plaque in patients with type 2 diabetes: an exploratory cross-sectional study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the associations of continuous ultrasound-derived fat fraction (UDFF) with carotid intima-media thickness (CIMT) and prevalent carotid plaque in patients with type 2 diabetes mellitus (T2DM), assess the incremental statistical information provided by UDFF in primary and broader traditional vascular-risk adjustment models, and compare its within-cohort discrimination with conventional qualitative liver ultrasonography. Methods: This single-center retrospective cross-sectional study included 153 patients with T2DM evaluated in the Department of Endocrinology, Affiliated Hospital of Jiangsu University, between September and December 2025. Continuous UDFF was the primary exposure. CIMT was analyzed using linear regression and prevalent carotid plaque using logistic regression. The primary multivariable model adjusted for age, sex, statin therapy, and low-density lipoprotein cholesterol (LDL-C). Results: Each 1-percentage-point increase in UDFF was associated with a 0.0105-mm higher CIMT (95% CI, 0.0080-0.0131; P<0.001) and 10.9% higher odds of prevalent carotid plaque (OR = 1.109, 95% CI, 1.056-1.164; P<0.001) after multivariable adjustment. Associations remained materially similar in broader covariate models and after excluding 28 participants with prior atherosclerotic cardiovascular disease. Adding UDFF to the primary clinical adjustment model increased R² for CIMT from 0.274 to 0.498 and the C-statistic for carotid plaque from 0.633 to 0.747 (DeLong P = 0.018). In the broader traditional vascular-risk model, the C-statistic increased from 0.697 to 0.758 (ΔC-statistic=0.061; DeLong P = 0.045). In otherwise identical clinical models, discrimination for prevalent carotid plaque was greater with continuous UDFF than with the original four-category conventional ultrasonographic steatosis grade (0.747 vs 0.657; DeLong P = 0.008). Conclusion: Higher UDFF was associated with greater CIMT and prevalent carotid plaque in patients with T2DM. UDFF provided incremental statistical information within this cohort, although the magnitude of improvement in plaque discrimination was smaller in the broader traditional vascular-risk model than in the primary clinical adjustment model. Continuous UDFF also showed greater within-cohort discrimination than conventional four-category ultrasonographic steatosis grading. These cross-sectional findings do not establish causality or prospective cardiovascular risk prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.